Despite positive clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial opposition from managed care entities. These insurers are typically building obstacles to reimbursement, including high cost restrictions and prior authorization that limit user access. Industry believe